Featured
GlucoStabilizer software has been validated to be safe and effective in attaining the prescribed glycemic targets with less hypoglycemia and glycemic variability across a variety of patient populations. These published research articles and posters can be accessed below.
GlucoStabilizer used to optimize glycemic targets for different patient populations which allowed for lower incidence of hypoglycemia.
GlucoStabilizer successfully used in the management of DKA with the avoidance of hypoglycemia.
GlucoStabilizer is efficacious and safe for treatment of patients with a primary diagnosis of DKA when compared to provider-driven insulin dosing.
GlucoStabilizer used in obstetrics can improve intrapartum glycemic management without increasing hypoglycemia in women with both pregestational and gestational diabetes mellitus that is treated with an insulin infusion.
GlucoStabilizer successfully manages patient’s blood glucoses in the intensive care unit of an acute care facility.
Converting from a paper-based protocol to GlucoStabilizer for intensive insulin therapy resulted in superior control of hyperglycemia and marked decrements in the incidence of hypoglycemia and glycemic variability.
Patients whose intensive insulin infusions were managed using the GlucoStabilizer software program, as compared to a traditional paper protocol achieved sustained tighter glycemic control.
GlucoStabilizer provides a safe and effective way to treat acute hyperglycemia in the pregnant population.
Glycemic control targeted to a lower glucose range was achieved using GlucoStabilizer and the risk of hypoglycemia experienced can be minimized.
Use of the GlucoStabilizer program in the ICU resulted in improved glycemic control compared to the previous manually calculated glycemic control protocols.